Evidence map›Paper›PMID 38061566›Full record

ReviewBiochimica et biophysica acta. Molecular cell research2024

Protein kinase D1 - A targetable mediator of pancreatic cancer development.

Alicia K Fleming Martinez, Peter Storz

Open access · greenAbstract readReview
In one paragraph

Review in Biochimica et biophysica acta. Molecular cell research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Alicia K Fleming MartinezDepartment of Cancer Biology, Mayo Clinic, Jacksonville, FL, USA.
Peter StorzDepartment of Cancer Biology, Mayo Clinic, Jacksonville, FL, USA. Electronic address: storz.peter@mayo.edu.
Mayo Clinic in Florida · US

Funding

Role of ICAM1 in development and progression of pancreatic cancerR01CA229560 · NCI · MAYO CLINIC JACKSONVILLE · PI STORZ, PETER · 2019 to 2023
$1.8M
NCI NIH HHS R01 CA229560
6 · The paper itself

Abstract

Members of the Protein kinase D (PKD) kinase family each play important cell-specific roles in the regulation of normal pancreas functions. In pancreatic diseases PKD1 is the most widely characterized isoform with roles in pancreatitis and in induction of pancreatic cancer and its progression. PKD1 expression and activation increases in pancreatic acinar cells through macrophage secreted factors, Kirsten rat sarcoma viral oncogene homolog (KRAS) signaling, and reactive oxygen species (ROS), driving the formation of precancerous lesions. In precancerous lesions PKD1 regulates cell survival, growth, senescence, and generation of doublecortin like kinase 1 (DCLK1)-positive cancer stem cells (CSCs). Within tumors, regulation by PKD1 includes chemoresistance, apoptosis, proliferation, CSC features, and the Warburg effect. Thus, PKD1 plays a critical role throughout pancreatic disease initiation and progression.

Indexed as

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsPancreatitisPrecancerous ConditionsDoublecortin-Like KinasesHumansProtein KinasesDCLK1 protein, humanDoublecortin-Like KinasesProtein KinasesPancreatic cancerPancreatic ductal adenocarcinomaPancreatic expressionPancreatitisPKDPrecancerous lesionsProgressionProtein kinase D

Identifiers

PMID38061566
PMCPMC10872883
OpenAlexW4389339773

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.